{
    "symbol": "PEN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-03 23:32:03",
    "content": " In our vascular business, we reported growth of 37.7% year-over-year to $122.8 million in the first quarter. This expanded partnership, which includes our older Indigo vascular thrombectomy products, but not Lightning 7 or 12 yet, occurred a quarter earlier than expected in contributed incremental $5 million to our first quarter revenue. Revenue from our vascular business grew to $122.8 million in the first quarter of 2022, an increase of 37.7% reported and 38.8% in constant currency compared to the same period last year. Revenue from our neuro business was $81.1 million in the first quarter of 2022, an increase of 1.3% reported and 2.9% in constant currency compared to the same period a year ago. Your line is open. Your line is open. Your line is open. Your line is open. I think over the past couple years or even prior to that compared to the North American business, you've always talked about there's been multiple entrants in this space and I\u2019m not sure, its known you from 10 to 15, really outside of these larger size competitors that have come in, and attempted to kind of take share in the space, but really hadn't had much of a meaningful impact, I guess, on the company's market share. Your line is open. Your line is open."
}